Liquid Biotech USA Raises $2M in Seed Capital

Liquid Biotech USA, Inc., a Philadelphia, PA-based developer of technology for cancer diagnostics and gene discovery, raised $2m in seed capital.

Oncolys Biopharma (TYO:4588) made the investment.

The company intends to use the funds to further develop its technology.

Led by Dr. Philip M. Sass, Chairman, President, and CEO, and Jeffrey M. Janco, Executive Vice President, Chief Operating Officer, Liquid Biotech USA is a spin out from the Penn Center for Innovation, the University of Pennsylvania’s commercialization organization, whose technology can identify, then isolate, individual circulating tumor cells (CTCs)—cells frequently found in the blood of cancer patients—from liquid biopsies.



Join the discussion